



Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY 1

Last Trade:	132.85
Trade Time:	1:00 PM ET 11.24.2017
Change:	0.52 (0.393%)
Day Range	131.00 - 134.89
52-Week Range	35.98 - 147.63
Volume	662,563
Market Cap. (\$M)	13,063.141
Shares Out (M)	98.330

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STAr): genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. These novel therapeutics carry the potential to transform the lives of patients who have limited or inadequate treatment options. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into a reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are i ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 11.20.2017 [U.S. Food and Drug Administration \(FDA\) Grants Alnylam Breakthrough Therapy Designation \(BTD\) for Patisiran for the Treatment of Hereditary ATTR \(hATTR\) Amyloidosis with Polyneuropathy](#)
- 11.16.2017 [Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares](#)
- 11.16.2017 [Alnylam Initiates Rolling Submission of New Drug Application \(NDA\) to U.S. Food and Drug Administration \(FDA\) for Patisiran for the Treatment of Hereditary ATTR \(hATTR\) Amyloidosis](#)
- 11.13.2017 [Alnylam Pharmaceuticals Prices Public Offering of Common Stock](#)
- 11.13.2017 [European Medicines Agency \(EMA\) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR \(hATTR\) Amyloidosis](#)

Events [\[View all \]](#)

- 11.29.2017 8:30 AM ET [29th Annual Piper Jaffray Healthcare](#)
- 11.29.2017 9:30 AM ET [Evercore ISI BioPharma Catalyst/Deep Dive Conference](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 11.07.2017 [Quarterly Report \(10-Q\)](#)
- 08.09.2017 [Quarterly Report \(10-Q\)](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)

